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Increased Platelet Activation in the Chronic Phase After
Cerebral Ischemia and Intracerebral Hemorrhage
Fop van Kooten, MD; Giovanni Ciabattoni, MD; Peter J. Koudstaal, MD, PhD;
Diederik W.J. Dippel, MD, PhD; Carlo Patrono, MD
Background and Purpose—Enhanced thromboxane (TX) biosynthesis has previously been reported in the acute phase
after ischemic stroke. We investigated whether enhanced urinary excretion of 11-dehydro-TXB2, a noninvasive index
of platelet activation, was present in the chronic phase after a transient ischemic attack (TIA) or stroke, including
intracerebral hemorrhage.
Methods—We obtained a single urinary sample from 92 patients between 3 and 9 months after onset of stroke or TIA. The
urinary excretion of the major enzymatic metabolite of TXA2, 11-dehydro-TXB2, was measured by a previously
validated radioimmunoassay. The excretion rates were compared with those of 20 control patients with nonvascular
neurological diseases.
Results—Urinary 11-dehydro-TXB2 averaged 2946139, 4136419, and 5576432 pmol/mmol creatinine for patients with
TIA, ischemic stroke, and intracerebral hemorrhage, respectively; the values were higher in all subgroups (P,0.01) than
that in control patients (119666 pmol/mmol). Increased 11-dehydro-TXB2 excretion was present in 59% of all patients,
in 60% (P,0.001) of patients with TIA, in 56% (P,0.001) of patients with ischemic stroke, and in 73% (P,0.001) of
patients with intracerebral hemorrhage. Atrial fibrillation, no aspirin use, and severity of symptoms at follow-up
contributed independently to the level of 11-dehydro-TXB2 excretion in a multiple linear regression analysis.
Conclusions—Platelet activation is often present in patients in the chronic phase after stroke, including those with
intracerebral hemorrhage. Persistent platelet activation, which is associated with atrial fibrillation and poor stroke
outcome, can be substantially suppressed by aspirin treatment. (Stroke. 1999;30:546-549.)
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In previous studies1–3 we have reported enhancedthromboxane (TX) biosynthesis, as reflected by the urinary
excretion of a major TXA2 metabolite, 11-dehydro-TXB2, in
patients with acute ischemic stroke. Increased TX production
was found to occur episodically during the first 2 to 3 days
after the onset of ischemic stroke1–3 and could be largely
suppressed by low-dose aspirin,1,3 thus suggesting its cyclo-
oxygenase-dependent formation in platelets. Repeatedly in-
creased 11-dehydro-TXB2 excretion was independently re-
lated to stroke severity and atrial fibrillation. However,
metabolite excretion was not a statistically significant inde-
pendent prognostic factor for outcome when added to stroke
syndrome or stroke severity in a multiple logistic regression
model, probably because of the rather small size of that
study.3 Whether increased 11-dehydro-TXB2 excretion is
detectable in the chronic phase after stroke, and whether this
is related to cardiovascular risk factors and stroke outcome, is
unknown.
In the present study we performed measurements of uri-
nary 11-dehydro-TXB2 excretion between 3 and 9 months
after stroke onset in patients with transient ischemic attack
(TIA), ischemic stroke, or intracerebral hemorrhage to inves-
tigate whether enhanced platelet activation is present in the
chronic phase after stroke, and if so, whether such persistent
platelet activation is associated with stroke type, cardiovas-
cular risk factors, and outcome.
Subjects and Methods
Study Patients
Patients were recruited from the hospital-based stroke cohort of the
Dutch Vascular Factors in Dementia Study, of which the inclusion
and exclusion criteria are detailed elsewhere.4 The most important
inclusion criteria for this study were that patients (1) had had
ischemic stroke, intracerebral hemorrhage, or TIA with neurological
deficit on admission to the hospital; (2) had a reasonable life
expectancy and were alive at follow-up; (3) were $55 years of age
at time of stroke onset; (4) were native Dutch speakers; and (5) were
not aphasic or were only mildly aphasic (,3 on the Aphasia Severity
Rating Scale of the Boston Diagnostic Aphasia Examination). Of the
300 patients who met these criteria, we used data from all nonde-
mented patients for whom urinary samples were available. To
achieve the demented/nondemented ratio of 1:4 that was found in the
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whole cohort,4 a random sample of demented stroke patients was
added to the study group. Detailed information about cardiovascular
risk factors and stroke characteristics was obtained during hospital
admission. In addition to a full neurological examination, ancillary
investigations consisted of standardized blood tests; a chest radio-
graph; brain CT and/or MRI; duplex scanning of the carotid arteries;
a cardiac analysis, including 12-lead ECG; and if indicated, 24-hour
ECG monitoring and ECG. At follow-up, between 3 and 9 months
after onset of stroke, blood pressure measurements were performed,
urinary samples were collected, and details about medication used at
the time of follow-up were obtained. Stroke severity was assessed by
means of the modified Rankin Scale.5
Control Patients
We used the data from our previous study,1 in which 11-dehydro-
TXB2 excretion was measured in 20 control patients (11 men and 9
women; mean age, 64.2 years; range, 41 to 85 years) with nonvas-
cular neurological disorders, such as minor cerebral trauma, Parkin-
son’s disease, epilepsy, or cervical spondylotic myelopathy, who
were admitted to the same hospital. Urine was collected during the
night as soon as possible after the patient’s admission to the hospital.
Urine Measurements
Urine samples were collected 3 to 9 months after stroke. The
creatinine concentration was measured, and samples of 50 mL were
immediately frozen and stored at 220°C until extraction. Analytical
measurements of 11-dehydro-TXB2 excretion were performed by
researchers blinded to clinical characteristics. Immunoreactive 11-
dehydro-TXB2 was extracted from 10-mL aliquots of each coded
urine sample (the pH was adjusted to 4.0 with formic acid) on
SEP-PAK C18 cartridges (Waters Associates) and eluted with ethyl
acetate. The eluates were subjected to silicic acid column chroma-
tography and further eluted with benzene/ethyl acetate/methanol
(60:40:30, vol/vol). Immunoreactive 11-dehydro-TXB2 eluted from
silicic acid columns was assayed at a final dilution of 1:30 to 1:1000,
as described previously.6 The urinary excretion rate of 11-dehydro-
TXB2 was expressed as picomoles per millimole of creatinine.
Statistical Analysis
Data were analyzed by means of Stata statistical software.7 The
Student t test was used to compare urinary 11-dehydro-TXB2
excretion between groups. Multiple linear regression was used to
assess the relationship between the level of 11-dehydro-TXB2
excretion and other clinical characteristics. Values of P,0.05 were
considered statistically significant.
Results
The present study group consisted of 92 patients (mean age,
73.868.2 years), of whom 53 were men and 39 women. Ten
(11%) had had a TIA, 71 (77%) ischemic stroke, and 11
(12%) intracerebral hemorrhage.
The individual values of 11-dehydro-TXB2 in all patients
and controls are depicted in Figure 1. These values ranged
from 105 to 496 (median, 287) pmol/mmol creatinine in
patients with TIA, 80 to 2105 (median, 290) in patients with
ischemic stroke, and 96 to 1467 (median, 466) in patients
with intracerebral hemorrhage. Compared with control pa-
tients, 11-dehydro-TXB2 excretion was significantly higher in
patients with TIA (P,0.001), patients with ischemic stroke
(P50.003), and in patients with intracerebral hemorrhage
(P,0.001). In 60% of the patients with TIA (P5,0.001),
56% of the patients with ischemic stroke (P,0.001), and
73% of the patients with intracerebral hemorrhage
(P,0.001), the excretion rate exceeded 2 SDs of the mean
value of control patients with nonvascular disorders (119666
pmol/mmol creatinine). Overall, persistently increased uri-
nary 11-dehydro-TXB2 excretion was present in 59% of the
patients. Table 1 shows the urinary 11-dehydro-TXB2 excre-
tion of the 92 patients on the basis of demographic charac-
teristics, cardiovascular risk factors, use of antiplatelet and
anticoagulant medication, and stroke characteristics. In the
univariate analysis, urinary 11-dehydro-TXB2 excretion was
significantly higher in women (P50.006) and in patients with
atrial fibrillation (P,0.001) or congestive heart failure
(P,0.001). Patients who used aspirin (n556) had signifi-
cantly lower excretion rates of 11-dehydro-TXB2 than pa-
tients on oral anticoagulant treatment or patients without
antiplatelet or anticoagulant treatment (P50.004). Mean 11-
dehydro-TXB2 excretion in patients with TIA was signifi-
cantly lower than that in patients with cerebral infarction or
intracerebral hemorrhage (P50.04). No association was
found between the level of 11-dehydro-TXB2 excretion and
subtype of cerebral infarction. Poor stroke outcome, as
measured by a Rankin Scale score of .3 at follow-up, was
associated with increased 11-dehydro-TXB2 excretion
(P,0.001).
Five patients had a recurrent vascular event between their
qualifying event and the time of urinary sampling during
follow-up. Three of them had an ischemic stroke, 1 a TIA,
and 1 an intracerebral hemorrhage. Urinary 11-dehydro-TXB2
excretion averaged 7166693 pmol/mmol creatinine and was
numerically higher (P50.09) than in patients without early
recurrence. The 3 patients with ischemic stroke recurrence
had significantly enhanced metabolite excretion: 9766840
pmol/mmol creatinine (P50.01).
In a multiple linear regression analysis, presence of atrial
fibrillation and severe strokes (Rankin Scale score of .3 at
follow-up) were independently associated with increased
11-dehydro-TXB2 levels whereas treatment with aspirin was
associated with reduced metabolite excretion (Table 2).
Individual measurements of urinary 11-dehydro-TXB2, plotted on
a log scale, for control patients (mean6SD, 119666 pmol/mmol
creatinine) and for patients with TIA (2946139), ischemic stroke
(4136419), and intracerebral hemorrhage (5576432).
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Discussion
The main finding of the present study is that biochemical
evidence of in vivo platelet activation is detectable in the
chronic phase after stroke in approximately 60% of patients.
In the present study, patients with intracerebral hemorrhage
and TIA were also included. Of the ischemic stroke patients,
56% had increased urinary 11-dehydro-TXB2 excretion in the
chronic phase. Perhaps unexpectedly, in the vast majority
(73%) of patients with intracerebral hemorrhage, we also
found enhanced TX biosynthesis. This finding may suggest
that increased platelet activation is a reflection of vascular
risk factors, diffuse atherosclerotic lesions, or the extent of
vascular damage due to the stroke. However, it is unlikely
that platelet activation merely reflects a generalized vascular
disease. A recent study in patients with peripheral arterial
disease has clearly demonstrated that hypertension, diabetes
mellitus, and hypercholesterolemia, but not peripheral vascu-
lar disease per se, are associated with enhanced TX biosyn-
thesis.8 In our study, we found no relationship between
hypertension, diabetes mellitus, and hypercholesterolemia on
the one hand and elevated levels of 11-dehydro-TXB2 excre-
tion on the other. However, two thirds of our patients were
using aspirin at the time of sampling. Davı` et al reported that
a daily regimen of low-dose aspirin could largely suppress
enhanced TX biosynthesis in patients with hypercholesterol-
emia9 and diabetes mellitus.10 The relatively small number of
patients with one or more vascular risk factors in our study
probably explains why adjustment for aspirin intake did not
eliminate its confounding effect in the multivariate analysis.
As in our previous study,3 presence of atrial fibrillation and
absence of aspirin therapy were associated with increased TX
production in the univariate analysis. We previously reported
that poor stroke outcome tended to be associated with
increased TX production in the acute phase. In the present
study, we found a statistically significant higher rate of TX
metabolite excretion in patients with a Rankin Scale score of
.3 at follow-up. The association between increased TX
production and atrial fibrillation may reflect, at least in part,
the fact that atrial fibrillation is more likely to cause severe
strokes. Moreover, patients with atrial fibrillation usually
receive oral anticoagulant treatment rather than aspirin. How-
ever, in the multiple regression analysis, both atrial fibrilla-
tion and stroke outcome were independently related to the
rate of urinary 11-dehydro-TXB2 excretion.
The study of Davı` et al8 suggests that persistently increased
platelet activation is a predictor of ischemic events in the
setting of peripheral arterial disease, since patients who
experienced vascular events (myocardial infarction, cardiac
death, ischemic stroke) during 48 months of follow-up had
significantly higher levels of 11-dehydro-TXB2 excretion at
baseline than patients who remained event free. Five of our
patients (5.4%), all of whom had had an ischemic stroke, had
a vascular event in the time between their qualifying stroke
and follow-up at 3 to 9 months later. In the 3 patients with
recurrent ischemic stroke, TX metabolite excretion was
significantly higher than in patients with no recurrences. This
could not be explained by acute episodes of platelet activation
due to the vascular event, because all patients were tested at
least 3 months after their last event. This procedure was part
TABLE 1. 11-Dehydro-TXB2 Excretion Values by Demographic
Factors, Cardiovascular Risk Factors, Medication, and
Stroke Characteristics
Characteristic n 11-Dehydro-TXB2 P
Age, y
,75 44 3856368 0.46
$75 48 4476433
Gender
Male 53 3206262 0.006
Female 39 5496512
Cardiovascular risk factors
Smoking 26 4086336 0.89
Hypertension 56 3716328 0.17
Diabetes mellitus 18 5136578 0.26
Hypercholesterolemia 30 3266188 0.13
Intermittent claudication 7 2626150 0.29
Angina pectoris 13 2476126 0.10
Atrial fibrillation 19 7596637 ,0.001
Congestive heart failure 7 8906611 ,0.001
History of cardiovascular disease
Myocardial infarction 9 3096154 0.40
Stroke 22 3656243 0.49
Retinal infarction 2 5176584 0.72
Medication
No oral anticoagulant and no
aspirin
10 6166412 0.13†
Aspirin 56 2946294 0.004*
Oral anticoagulant 26 6066500 0.95*
Type of stroke
TIA 10 2946139 0.04
Cerebral infarction 71 4136419 0.83
Intracerebral hemorrhage 11 5576432 0.27
Clinical subtype cerebral infarction
TACS 7 4626332 0.70
PACS 32 3746364 0.48
LACS 25 4346520 0.78
POCS 7 4656395 0.72
Severity
Rankin score at follow-up #3 76 3206229 ,0.001
Rankin score at follow-up .3 16 8776667
n is number of patients; values are mean6SD. TACS indicates total anterior
circulation stroke; PACS, partial anterior circulation stroke; LACS, lacunar
stroke; and POCS, posterior circulation stroke.
*vs no oral anticoagulant and no aspirin; †vs aspirin or oral anticoagulant.
TABLE 2. Coefficients With 95% CIs of Factors That Remained
Independently Related to 11-Dehydro-TXB2 Excretion in a
Multiple Linear Regression Analysis
Factor Coefficient 95% CI P
Aspirin 2224 2355–294 0.001
Atrial fibrillation 291 133–449 ,0.001
Severe stroke 507 346–668 ,0.001
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of the protocol.4 Although the number of patients is small and
the samples were taken after the recurrent event, the findings
are in line with those of Davı` et al8 in a different clinical
setting. Whether persistent platelet activation is a risk factor
for recurrent ischemic events in patients with ischemic and
hemorrhagic stroke remains to be investigated in larger
studies with longer follow-up.
We conclude that platelet activation is often present in
patients in the chronic phase after stroke, including those with
intracerebral hemorrhage. Persistent platelet activation,
which is associated with atrial fibrillation and poor stroke
outcome, can be substantially suppressed by aspirin
treatment.
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